CERo Therapeutics Holdings, Inc. (CERO)
- Previous Close
1.1600 - Open
1.1100 - Bid 1.1400 x 100
- Ask 1.1800 x 100
- Day's Range
1.1100 - 1.1999 - 52 Week Range
1.1100 - 12.8000 - Volume
103,158 - Avg. Volume
1,133,396 - Market Cap (intraday)
16.859M - Beta (5Y Monthly) -0.06
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
www.cero.bioRecent News: CERO
Performance Overview: CERO
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CERO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CERO
Valuation Measures
Market Cap
17.08M
Enterprise Value
14.55M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-7.20%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.54M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
96.87k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
5.11M
Research Analysis: CERO
Company Insights: CERO
CERO does not have Company Insights